Skip to search formSkip to main contentSkip to account menu

Procysteine

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

2-oxothiazolidine-4-carboxylic acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Alveolar type II cells from ethanol-fed rats produce a fibronectin-enriched extracellular matrix that promotes monocyte activation.
Highly Cited
2002
Highly Cited
2002
Glutathione replacement preserves the functional surfactant phospholipid pool size and decreases sepsis-mediated lung dysfunction in ethanol-fed rats.
BACKGROUND Alcohol abuse increases the incidence of acute respiratory distress syndrome (ARDS). Previous evidence from our… 
1998
1998
Elevation of whole-blood glutathione in peritoneal dialysis patients by L-2-oxothiazolidine-4-carboxylate, a cysteine prodrug (Procysteine).
Glutathione is a major cellular antioxidant that protects protein thiols and inhibits cellular damage due to oxygen free radicals… 
1998
1998
A Phase I/II Evaluation of Oral L‐2‐Oxothiazolidine‐4‐Carboxylic Acid in Asymptomatic Patients Infected with Human Immunodeficiency Virus
A randomized double‐blind, placebo‐controlled study was conducted in 37 asymptomatic HIV‐infected individuals (mean CD4 count 707… 
1997
1997
Protective effects of L-2-oxothiazolidine-4-carboxylate treatment on cyclophosphamide-induced cystitis in rats.
1996
1996
Supplementation with L-2-oxothiazolidine-4-carboxylic acid, a cysteine precursor, does not protect against lipid peroxidation in puromycin aminonucleoside-induced nephropathy.
Lipid peroxidation in the kidney has been shown to precede proteinuria in puromycin aminonucleoside (PAN)-induced nephropathy… 
1995
1995
L-2-oxothiazolidine-4-carboxylic acid (procysteine) inhibits expression of the human immunodeficiency virus and expression of the interleukin-2 receptor alpha chain.
These studies were undertaken to examine the in vitro effects of the cysteine pro-drug L-2-oxothiazolidine-4-carboxylic acid… 
1994
1994
A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects.
Twenty-four asymptomatic, HIV-1-seropositive subjects with CD4 cell counts of > or = 400/microliters participated in a Phase I/II… 
1994
1994
Development of a novel glutathione repleting agent, L-2-oxothiazolidine-4-carboxylic acid (Procysteine®)
A number of disease states are associated with episodes of acute or chronic oxidative stress, including Acute Respiratory… 
1993
1993
Enhancement of viability of human peritoneal mesothelial cells with glutathione precursor: L-2-oxothiazolidine-4-carboxylate.
This study tested the effect of L-2-oxothiazolidine-4-carboxylate (procysteine), a precursor of the intracellular cysteine, on… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)